Blood-brain-barrier permeability of escitalopram depending on genetic polymorphisms of the ABCB1-gene: effect on sleep and procedural learning
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Escitalopram (Primary)
- Indications Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Premenstrual dysphoric disorder; Social phobia
- Focus Pharmacogenomic; Pharmacokinetics
- 27 Mar 2019 Biomarkers information updated
- 11 May 2011 Planned end date changed from 1 Jun 2009 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 21 Apr 2008 The expected completion date for this trial is now 1 Jun 2009, according to clinicaltrials.gov.